Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBG131 CAR-T in CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
NCT07394205Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBG131 in gastric cancer (GC) and pancreatic cancer (PC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Incidence and Grading of Adverse Events and Serious Adverse Events at 15 years, Incidence and Determination of Dose-Limiting Toxicity at 28 days and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CBG131
03
Conditions
gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07394205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394205.